Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment

Case Reports in Oncology

Volumn 4, Issue 1, 2011, Pages 229-235

  Farr, Katherina Podlekareva ^a   Safwat, Akmal ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hand foot syndrome; Palmar plantar erythrodysesthesia; Pegylated liposomal doxorubicin

Indexed keywords

ANALGESIC AGENT; DOXORUBICIN; EMOLLIENT AGENT; PYRIDOXINE; STEROID;

AGED; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; ERYTHEMA; FEMALE; FRICTION; HAND FOOT SYNDROME; HOSPITALIZATION; HUMAN; MEDLINE; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SWELLING; ULCER; ULCER HEALING;

EID: 79957602097     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000327767     Document Type: Article

References (14)

1. Webster-Gandy JD, How C, Harrold K: Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-246.
2. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449. (Pubitemid 38444547)
3. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322. (Pubitemid 32642183)
4. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G: Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007;18:1159-1164. (Pubitemid 47244360)
5. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-2173.
6. Charrois GJ, Allen TM: Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663:167-177. (Pubitemid 38625591)
7. Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, et al: Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1211. (Pubitemid 41418329)
8. Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK: Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol 2009;114:219-224.
9. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J: Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer 2008;16:267-273. (Pubitemid 351422803)
10. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, et al: Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004;100:1199-1207. (Pubitemid 38325948)
11. Lee S, Lee S, Chun Y, et al: Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study (abstract). Proc Am Soc Clin Oncol 2007;25:9007.
12. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567-1571. (Pubitemid 28265245)
13. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E: Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008;108:332-335.
14. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, et al: Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer 2008;44:781-790.